Second-quarter GAAP margin rose to 11.90 percent from 9.70 percent. Charles River Laboratories stock

Charles River Laboratories International (CRL) drew fresh attention after quarterly revenue of US$1.00b came in 2.5% above analyst expectations, with organic sales and EPS also beating estimates and the share price climbing 31.5% since the report. The recent earnings beat has come on top of a sharp share price move. Charles River Laboratories International has posted a 90 day share price return of 33.8% and a year to date gain of 48.3%, while the 1 year total shareholder return is 68.1%. This...

Charles River Laboratories International (CRL) drew fresh attention after quarterly revenue of US$1.00b came in 2.5% above analyst expectations, with organic sales and EPS also beating estimates and the share price climbing 31.5% since the report. The recent earnings beat has come on top of a sharp share price move. Charles River Laboratories International has posted a 90 day share price return of 33.8% and a year to date gain of 48.3%, while the 1 year total shareholder return is 68.1%. This...

Results are due November 4, 2026. Charles River Laboratories stock was EUR 267.10 on October 16, 202

Revenue fell 2.7 percent to USD 1.00 billion. Charles River Laboratories stock costs EUR 275.40 on O

Charles River Laboratories International and Magellan Stem Cells recently agreed to a collaboration that applies Charles River’s biologics quality control, cGMP viral testing, and development support to Magellan’s stem cell therapies as Magellan prepares a Phase III program for its Zelestrocel osteoarthritis candidate. The partnership gives Charles River deeper exposure to late-stage cell therapy programs and highlights its push into NGS-based testing and alternative methods that reduce...